PIOMBINO DESE, Italy / Sep 19, 2023 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will livestream its inaugural Capital Markets Day on September 27, 2023 from 11:00 a.m. ET to approximately 2:30 p.m. ET.
The livestream will be available at https://ir.stevanatogroup.com/news-events/ir-calendar, and supporting materials will be made available online the morning of the event.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit: www.stevanatogroup.com.
Last Trade: | US$22.94 |
Daily Change: | -1.00 -4.18 |
Daily Volume: | 325,639 |
Market Cap: | US$1.140B |
November 11, 2024 November 05, 2024 October 01, 2024 August 29, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load